Clinical Trial Update: 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating 131I-rituximab for relapsed or refractory follicular lymphoma or mantle cell lymphoma is reported; current status is unknown…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• 131I-rituximab

Snippet

Sponsor: Korea Cancer Center Hospital | Conditions: Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma | Phase 2 | Status: UNKNOWN